Quantcast

Latest IMS Health Stories

2014-09-16 23:13:20

InTouchMD™ launches innovative social media tool that allows pharmaceutical companies and physicians to better connect with their patients. Garden City, NY (PRWEB) September 16, 2014 InTouchMD, a New York based multi-channel contact center dedicated to serving the healthcare industry, has launched a revolutionary service that gives pharmaceutical companies the ability to connect to their patients through social media in order to foster better patient diagnostics and care. “We have...

2014-09-08 08:30:45

NEW YORK, Sept. 8, 2014 /PRNewswire/ -- Everyday Health, Inc. (NYSE: EVDY), a leading digital health and wellness company, today announced the appointment of Miki Kapoor as President of Healthcare Solutions. In this newly created role, Mr. Kapoor will be responsible for executing Everyday Health's growth strategy across the broader healthcare landscape and generating meaningful revenue from new customers channels. http://photos.prnewswire.com/prnvar/20101112/NY00568LOGO As payors,...

2014-09-05 08:23:21

PITTSBURGH, Sept. 5, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Ibandronate Sodium Injection, 1 mg (base)/mL, packaged in 3 mg (base)/3 mL pre-filled glass syringes, which is the generic version of Hoffmann-La Roche's Boniva® Injection. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of osteoporosis in...

2014-08-22 08:24:49

PITTSBURGH, Aug. 22, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), which is the generic version of Upsher-Smith's Klor-Con®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of patients with hypokalemia, with or without metabolic...

2014-08-18 12:27:43

DALLAS, Aug. 18, 2014 /PRNewswire/ -- NorthStar Anesthesia has appointed Jeremiah Radandt chief financial officer. http://photos.prnewswire.com/prnvar/20140818/136934 Radandt brings significant health care leadership experience to his new role. In his most recent position, he served as chief financial officer for Primary Children's Hospital, a unit of Intermountain Healthcare that ranked in eight separate categories in U.S.News & World Report's Best Children's Hospitals for...

2014-07-23 12:31:16

Study quantifies lost savings from REMS and related restricted access tactics WASHINGTON, July 23, 2014 /PRNewswire-iReach/ -- Use of Risk Evaluation and Mitigation Strategies (REMS) and other restricted access programs to delay generic market entry results in $5.4 billion in lost savings annually, according to a new survey and analysis by economic consulting firm Matrix Global Advisors (MGA). Logo - http://photos.prnewswire.com/prnh/20140723/129680 Required by the Food and Drug...

2014-07-18 08:26:19

MUMBAI, July 18, 2014 /PRNewswire/ -- Aegis Limited, a leading outsourcing and technology services company, today announced that it has been recognized as a Major Player in the IDC Marketscape: Worldwide Business Analytics BPO Services 2014 Assessment (doc #249299, June 2014). IDC Marketscape measures key strategy of a service provider success across two primary categories - capabilities and strategies. (Logo: http://photos.prnewswire.com/prnh/20120710/NY37889LOGO )...

2014-07-08 08:30:07

PITTSBURGH, July 8, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, the generic version of Boehringer Ingelheim's Micardis® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of hypertension, to lower blood pressure. Telmisartan Tablets USP, 20 mg, 40 mg and 80...

2014-06-11 12:29:06

PITTSBURGH, June 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Risedronate Sodium Tablets USP, 150 mg, the generic version of Warner Chilcott's Actonel(®) Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Risedronate Sodium Tablets USP, 150 mg, had...

2014-06-09 08:28:26

PITTSBURGH, June 9, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Carboplatin Injection, 50 mg/5 ml, in multi-dose vials, which is the generic version of Bristol-Myers Squibb's Paraplatin(®) Injection. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the initial treatment of advanced ovarian carcinoma in established combination...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.